Pharmaco-epigenomics

dc.contributor.authorGündüz, Mehmet
dc.contributor.authorAcar, Muradiye
dc.contributor.authorErdogan, Kubra
dc.contributor.authorCetin, Elif Nihan
dc.contributor.authorGündüz, Esra
dc.date.accessioned2025-10-24T18:06:40Z
dc.date.available2025-10-24T18:06:40Z
dc.date.issued2013
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractEpigenetic modifications are defined as the study of heritable changes in phenotype that do not involve alterations in the DNA sequence. DNA methylation, posttranslational modifi cations of the histone proteins, and miRNAs are regulating the expression of genes as well as drug- metabolizing genes. Epigenetic regulation is essential for normal developmental and cellular processes. Conversely, abnormal epigenetic regulation is a character of complex diseases, including cancer, hematological malignancies, psychiatric disorders, and other diseases. Pharmaco-epigenomics is a novel discipline and involves the study of epigenetic factors in the interpersonal variation to drugs. Epigenetic biomarkers can be used to diagnose disease, estimate disease progression, or predict interpersonal variations in response to therapy. Unlike genetic alterations, changes in epigenetic machinery are reversible, and this reversible characteristic makes them an attractive therapeutic targets. © 2018 Elsevier B.V., All rights reserved.
dc.identifier.doi10.1007/978-81-322-1184-6_4
dc.identifier.endpage75
dc.identifier.isbn9788132211839
dc.identifier.isbn9788132211846
dc.identifier.scopus2-s2.0-84956814443
dc.identifier.scopusqualityN/A
dc.identifier.startpage63
dc.identifier.urihttps://doi.rog/10.1007/978-81-322-1184-6_4
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3122
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherSpringer India
dc.relation.publicationcategoryKitap Bölümü - Uluslararası
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzScopus_20251023
dc.subject[No keyword]
dc.titlePharmaco-epigenomics
dc.typeBook Chapter

Dosyalar